Drug intelligence / Profile preview

KP12301

Development stage: Preclinical
Lead developer: Korea Pharma
Modality: Small Molecules

Overview

KP12301 is a preclinical-stage therapeutic candidate being developed by Korea Pharma for the treatment of ulcerative colitis. Korea Pharma is a South Korean pharmaceutical company that focuses on various therapeutic areas, including central nervous system (CNS) disorders and gastrointestinal diseases. KP12301 is currently listed in the company's research and development pipeline as a treatment for inflammatory bowel disease, specifically ulcerative colitis. As of 2024, the drug remains in early-stage development, and its specific molecular target and mechanism of action have not been publicly disclosed by the developer.

Beyond the preview

Go deeper on KP12301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KP12301.

Explore the full profile